Acute Flaccid Myelitis (AFM)

Types
Causes
Symptoms
Diagnostic tests
Non-pharmacological treatments
Drug treatments
Dietary and “molecular” supplements
Regeneration-focused therapies
Procedures and surgeries
Prevention points
When to see doctors
What to eat and what to avoid
Frequently asked questions

Acute flaccid myelitis (AFM) is a sudden illness that damages the gray matter of the spinal cord, especially the front (anterior horn) cells that control muscles. Because these motor nerve cells are injured, muscles become weak, soft, and loose (flaccid). AFM often starts after a mild fever, cough, or stomach bug. Then, within hours to a few days, one or more limbs become weak. The weakness is usually asymmetric (worse on one side) and can involve the face, neck, or breathing muscles. Feeling (sensation) is often normal or only slightly changed, which helps doctors tell AFM apart from other diseases. MRI of the spinal cord shows bright signals in the gray matter. Nerve tests show a “motor neuron” pattern. AFM is most often linked to certain enteroviruses, like enterovirus D68 or A71, but the exact cause is not always found. Children are affected more than adults.

Acute flaccid myelitis is a rare but serious disease that suddenly weakens one or more limbs. It mainly affects the gray matter of the spinal cord—the area that carries signals from the brain to the muscles. Because the gray matter is inflamed and injured, the muscles lose their normal tone and reflexes and become “floppy” or “flaccid.” The weakness often follows a cold-like or flu-like illness caused by a virus, especially some enteroviruses such as EV-D68 or EV-A71. AFM can also involve the brainstem and the nerves that help us breathe, swallow, or move the face and eyes. Most patients are children, but adults can be affected. There is no FDA-approved medicine that cures AFM. Care focuses on fast recognition, hospital support (especially breathing support if needed), careful rehabilitation, and selected procedures for long-term function. Recovery varies. Some children recover well; others have lasting weakness even with excellent care. CDC+1MedlinePlusPMCThe Lancet

Other names

AFM is also known as “acute flaccid paralysis due to spinal gray matter myelitis,” “poliomyelitis-like syndrome,” “non-polio acute flaccid paralysis with anterior horn cell involvement,” and, in older literature, “poliomyelitis-like myelitis.” These names describe the same idea: a sudden paralysis with damage to the motor nerve cells in the spinal cord. “Polio-like” does not mean it is caused by poliovirus; most modern AFM is not polio. The term AFM is preferred because it is precise, based on MRI patterns, and separates this condition from other causes of limp weakness such as Guillain-Barré syndrome.

Types

By suspected trigger.

Viral-associated AFM: linked to non-polio enteroviruses (e.g., EV-D68, EV-A71) and, less often, other neurotropic viruses. 2) Probable para-infectious AFM: weakness appears days after a viral-like illness, but a specific virus is not confirmed. 3) Polio-associated AFM: rare today, seen where poliovirus still circulates.

By anatomic distribution.

Cervical-predominant AFM: mainly arms, neck, and sometimes face/breathing muscles. 2) Thoracic-predominant AFM: trunk weakness and posture problems. 3) Lumbosacral-predominant AFM: mainly legs. Many patients have mixed levels.

By clinical course.

Monophasic acute AFM: a single sudden episode with stabilization over days to weeks. 2) Recurrent AFM (very uncommon): new episodes separated by time, usually again following infections.

By severity.

Mild: one limb with partial weakness. 2) Moderate: multiple limbs, activities limited. 3) Severe: bulbar or breathing muscle involvement, intensive care needed.

Causes

Note: In AFM, “cause” often means a trigger found around the time symptoms start. A definite cause is not identified in every patient.

Enterovirus D68 (EV-D68).
This respiratory virus has been strongly linked with AFM waves in late summer and fall. Children often first have cough or runny nose. A few days later weakness starts. EV-D68 can infect motor neurons, leading to the specific gray matter injury seen on MRI.
Enterovirus A71 (EV-A71).
EV-A71, a common cause of hand-foot-mouth disease and brainstem encephalitis, can also cause AFM. When EV-A71 is the trigger, cranial nerve symptoms (face, swallowing, speech) can be prominent because the virus can affect the brainstem as well as the spinal cord.
Coxsackie A and B viruses (non-polio enteroviruses).
These viruses usually cause mild fever or sore throat. Rarely, they invade nervous tissue and target anterior horn cells, producing sudden flaccid weakness typical of AFM.
Poliovirus (rare where polio is controlled).
Polio classically damages motor neurons and causes flaccid paralysis. In countries with high vaccine coverage, polio-associated AFM is now rare; however, it remains a cause in areas with ongoing poliovirus transmission.
Parechoviruses.
Parechovirus infections occur in children and infants and can involve the central nervous system. In occasional reports, a parechovirus infection preceded AFM-like paralysis.
West Nile virus.
This mosquito-borne virus can attack motor neurons and produce a poliomyelitis-like paralysis with asymmetrical limb weakness, sometimes in adults, making it an important AFM trigger to test for during mosquito season.
Japanese encephalitis virus (travel or endemic regions).
Though better known for brain inflammation, it can involve the spinal gray matter and lead to flaccid limb weakness resembling AFM in some cases.
Zika virus (less common).
Zika is more often associated with Guillain-Barré syndrome or congenital effects, but rare reports describe anterior horn involvement and AFM-like weakness after infection.
Adenovirus coinfection (association).
Adenovirus primarily causes respiratory illnesses. Sometimes it is detected alongside enteroviruses during AFM workups. On its own, it is not a proven AFM driver, but coinfection can occur when respiratory viruses circulate together.
Herpesviruses (HSV, VZV, HHV-6) (uncommon).
These viruses may cause myelitis. When the gray matter is the main target and the pattern fits AFM, clinicians consider them possible but less frequent triggers, particularly if there are typical rashes or encephalitis signs.
Epstein–Barr virus (EBV) (rare).
EBV can affect the nervous system in unusual ways. Rare case reports describe AFM-like myelitis after EBV infection, often with concurrent sore throat and lymph node swelling.
Cytomegalovirus (CMV) (rare).
CMV myelitis may involve both white and gray matter. In immunocompromised hosts, CMV can damage anterior horn cells and mimic AFM.
Influenza viruses (rare).
Influenza may trigger various neurologic complications. AFM-like presentations are rare but have been described, especially in the setting of severe systemic illness.
Measles or mumps (very rare in vaccinated populations).
These viruses can cause nervous system disease. In locations with low vaccine coverage, clinicians keep them in the differential for AFM-like paralysis.
Enterovirus/rhinovirus mixed detection.
Respiratory swabs sometimes detect “rhinovirus/enterovirus.” Because the assay groups them, precise typing is needed. When the true agent is an enterovirus, AFM risk is relevant.
Para-infectious immune response.
Sometimes the virus is not found, yet timing suggests the immune system reacted to a recent infection and injured motor neurons. This para-infectious mechanism is considered in “probable” AFM.
Host genetic susceptibility.
Not every exposed child develops AFM. Subtle differences in antiviral defenses and neuron repair may raise individual risk. Research suggests innate immune pathways could matter.
Age (childhood vulnerability).
AFM mainly affects young children. Developing immune systems and still-maturing motor circuits may make the spinal gray matter more vulnerable to certain viruses.
Seasonality and community outbreaks.
AFM clusters often follow late-summer respiratory virus surges. A high community viral load increases the chance that a susceptible child encounters a neurotropic strain.
Polio vaccine-preventable gaps (public health factor).
In areas with low polio vaccination, poliovirus can circulate and cause polio-AFM. Strong routine immunization prevents this cause.

Symptoms

Sudden limb weakness.
A child who was running yesterday may not be able to lift an arm or stand today. The weakness often starts quickly and may worsen over 24–72 hours.
Asymmetry.
One side can be much weaker than the other. For example, the right arm may be flaccid while the left arm can still move.
Low muscle tone (flaccidity).
Muscles feel soft and floppy rather than stiff. Limbs may hang and lack resistance when moved.
Loss of reflexes.
Knee-jerk and other deep tendon reflexes in the weak limbs are reduced or absent because the motor arc is broken.
Neck or back pain at onset.
Some children complain of neck, shoulder, or back pain just before weakness appears, reflecting irritation of spinal nerve cells.
Facial weakness.
Smile may be uneven, eyelid may droop, or eye movement may be limited if cranial motor nerves or brainstem nuclei are affected.
Trouble swallowing or speaking.
Bulbar muscle weakness can cause slurred speech, nasal voice, choking on liquids, or drooling.
Breathing difficulty.
If the diaphragm or intercostal muscles weaken, breathing becomes shallow or fast. This is an emergency and needs immediate care.
Head lag or neck weakness.
Children may not be able to hold up the head. This suggests cervical cord gray matter involvement.
Hand or foot drop.
Wrist or ankle may hang down due to weak extensor muscles, leading to difficulty grasping or walking.
Gait changes.
Children may limp, trip, or refuse to bear weight. The leg may buckle because the quadriceps or hip muscles are weak.
Fatigue with activity.
Even mild tasks can be tiring because the number of working motor neurons is reduced.
Mild sensory changes or pain in limbs.
Sensation is usually near normal, but aching or tingling can occur due to inflamed roots or muscles.
Autonomic signs (sometimes).
Constipation, urinary retention, or temperature instability may occur if autonomic pathways are irritated, though this is less common.
Fever or cold symptoms days before weakness.
A runny nose, cough, or fever shortly before paralysis hints at a viral trigger.

Diagnostic tests

A) Physical examination (bedside)

General neurologic exam.
The clinician checks alertness, cranial nerves, strength, reflexes, tone, coordination, and sensation. In AFM, strength is decreased in specific muscles, tone is low, and reflexes are absent in the weak limbs. Sensation is often spared.
Manual muscle testing (MRC scale).
Each major muscle group is scored from 0 (no movement) to 5 (normal). AFM shows focal or asymmetric low scores, mapping which spinal segments are affected.
Reflex testing.
Tendon hammers are used to elicit knee, ankle, biceps, and triceps reflexes. AFM typically shows reduced or absent reflexes in the weak limbs due to motor neuron injury.
Cranial nerve and bulbar function exam.
Facial movement, palate elevation, tongue strength, swallowing, and speech are assessed. Abnormal findings point to brainstem involvement, common in some AFM cases.
Respiratory assessment at bedside.
Doctors observe breathing rate, chest rise, use of accessory muscles, and listen with a stethoscope. Any sign of shallow breathing or fatigue prompts urgent testing and support.

B) “Manual” or focused functional tests (simple, bedside measurements)

Grip strength (hand dynamometry or examiner resistance).
Measures hand power quickly. In AFM, grip may be weak on one side or both, helping track recovery over time.
Head-hold and neck-flexion test.
Child is asked to lift and hold the head off the bed. In cervical-predominant AFM, the head may flop back due to neck flexor weakness.
Single-leg stance and heel/toe walk (if safe).
These simple tasks reveal ankle and hip weakness. AFM patients may be unable to stand on toes or heels on the affected side.
Peak cough flow or simple cough effort.
Weak bulbar and chest muscles reduce cough strength. A poor cough suggests higher risk of pneumonia and may trigger respiratory support plans.
Swallow screening (water swallow, bedside).
Careful bedside swallowing checks look for choking or a wet, gurgly voice. Failure prompts formal speech-language evaluation.

C) Laboratory and pathological tests

Cerebrospinal fluid (CSF) analysis (lumbar puncture).
CSF often shows a mild increase in white cells (pleocytosis) and normal or mildly elevated protein. This pattern supports viral-associated spinal cord inflammation focused on gray matter.
CSF viral PCR and metagenomic sequencing.
Tests look for enteroviruses (EV-D68, EV-A71) and other neurotropic viruses. Even if negative, timing matters; viruses are sometimes hard to detect in CSF in AFM.
Respiratory swab PCR (nasopharyngeal).
Swabs can detect circulating viruses such as EV-D68. Identifying a compatible virus during an AFM cluster strengthens the suspected cause.
Stool PCR (for poliovirus and enteroviruses).
Because poliovirus is shed in stool, stool testing is essential when polio is possible. Non-polio enteroviruses can also be found.
Serum antibody testing (acute and convalescent).
Paired blood samples can show rising antibodies to a virus, suggesting recent infection. This helps when direct PCR studies are negative.
Autoimmune and inflammatory panels (to exclude mimics).
Blood and CSF tests check for conditions like neuromyelitis optica spectrum disorder, MOG-antibody disease, or systemic inflammation that can cause other forms of myelitis.

D) Electrodiagnostic tests

Nerve conduction studies (NCS).
Electrodes measure how well nerves conduct signals. AFM shows reduced motor responses (CMAPs) with relatively preserved sensory responses, fitting motor neuron/axonal injury rather than a sensory neuropathy.
Needle electromyography (EMG).
A tiny needle records muscle electrical activity. In AFM, EMG shows denervation (fibrillation potentials) and reduced motor unit recruitment in affected muscles, confirming anterior horn cell or motor axon damage.
F-waves and H-reflexes.
These specialized reflex measures can be reduced or absent in AFM-affected segments, supporting a motor pathway lesion at the spinal level.
Somatosensory evoked potentials (SSEPs) (optional).
SSEPs often remain near normal in AFM because sensory pathways are mostly spared. Normal SSEPs with severe weakness support the AFM pattern and help exclude other diseases.

E) Imaging tests

MRI of the spine with and without contrast (core test).
MRI shows long segments of T2-bright signal in the central gray matter, especially the anterior horns, often across multiple vertebral levels. Enhancement can be mild. This imaging pattern is the hallmark of AFM.
MRI of the brain and brainstem.
This looks for involvement of motor nuclei and tracks complications. When bulbar signs are present, brainstem MRI may show similar gray-matter changes.
Diffusion-weighted MRI (DWI).
DWI can highlight very early changes in affected gray matter, helping confirm AFM during the acute window when other sequences look subtle.
Diaphragm ultrasound (supportive).
Bedside ultrasound can show poor diaphragm movement in children with breathing weakness, guiding the need for ventilatory support.
Chest imaging (as needed).
While not diagnostic for AFM, a chest X-ray or low-radiation chest imaging can help monitor pneumonia risk if swallowing or cough is weak.

Non-pharmacological treatments

How to read this section: each item includes a brief description (~100–150 words), its purpose, mechanism, and benefits. These methods are part of a comprehensive rehab plan led by pediatric neurology, physiatry, physical therapy, occupational therapy, speech-language pathology, and respiratory therapy. They complement, not replace, medical care.

Physiotherapy interventions

Early passive range-of-motion (PROM).
Description: Gentle daily movements of shoulders, elbows, wrists, hips, knees, and ankles through their normal ranges. Therapists stabilize joints and move them without the patient using muscle power. Splints may be used between sessions.
Purpose: Prevent joint stiffness and contractures while the spinal cord heals.
Mechanism: Maintains capsule length, tendon glide, and soft-tissue elasticity; supports synovial fluid flow.
Benefits: Preserves alignment and comfort, reduces pain from tightness, and makes later active training more effective.
Active-assisted and active exercises.
Description: When flickers of movement return, the therapist helps the limb move with slings, elastic bands, or the other hand, then gradually reduces assistance.
Purpose: Rebuild muscle activation and endurance.
Mechanism: Repeated, task-oriented practice drives neuroplasticity in surviving motor units.
Benefits: Earlier functional gains and less learned non-use.
Task-specific gait training with body-weight support.
Description: Treadmill or over-ground walking while a harness unloads part of the body weight; may add robotic step devices.
Purpose: Relearn stepping patterns safely.
Mechanism: Repetitive sensory input to central pattern generators in the spinal cord.
Benefits: Improves walking speed, balance, and confidence.
Functional electrical stimulation (FES).
Description: Small surface electrodes stimulate weak muscles during tasks (e.g., ankle dorsiflexion during swing).
Purpose: Assist movement and strengthen target muscles.
Mechanism: Timed stimulation recruits motor units and reinforces brain-muscle connections.
Benefits: Better limb positioning, prevention of foot drop, smoother gait.
Respiratory physiotherapy and incentive spirometry.
Description: Breathing exercises, cough assist devices, and chest physiotherapy; teaches deep breaths and safe coughing.
Purpose: Support ventilation, protect lungs, and prevent atelectasis or pneumonia when trunk or diaphragm is weak.
Mechanism: Expands alveoli and mobilizes mucus.
Benefits: Fewer respiratory complications and shorter hospital stays. CDC
Postural control and core stabilization.
Description: Seated and standing balance drills with wedges, therapy balls, and trunk bracing.
Purpose: Improve midline control for sitting, transfers, and walking.
Mechanism: Activates trunk extensors and abdominals to stabilize the spine.
Benefits: Safer mobility and reduced fatigue.
Constraint-induced movement practice (CIMT) for an affected arm.
Description: Temporarily limit the stronger arm to encourage use of the weaker arm during structured tasks.
Purpose: Overcome learned non-use.
Mechanism: Intensive, task-oriented repetition promotes synaptic strengthening.
Benefits: Better hand use for dressing, feeding, and writing.
Aquatic therapy.
Description: Exercises in warm water to reduce load and allow practice of bigger movements.
Purpose: Enable safe range and strengthening when land training is hard.
Mechanism: Buoyancy decreases joint stress; hydrostatic pressure aids venous return.
Benefits: Increased tolerance, less pain, improved confidence.
Progressive resistance training (as reinnervation appears).
Description: Careful loading with bands/weights once EMG or clinical signs show reinnervation.
Purpose: Build strength without overfatigue.
Mechanism: Hypertrophy of recovering fibers; improved motor unit recruitment.
Benefits: Faster return to function and sport.
Orthoses, splinting, and serial casting.
Description: Night splints, ankle-foot orthoses, wrist/hand splints; serial casts for tight calves or hamstrings.
Purpose: Maintain neutral alignment and prevent deformity.
Mechanism: Prolonged low-load stretch remodels connective tissue.
Benefits: Better gait and hand positioning, fewer contractures.
Neuromuscular re-education with biofeedback.
Description: EMG or visual feedback to “teach” activation of specific weak muscles.
Purpose: Improve selective control.
Mechanism: Real-time feedback improves cortical motor planning.
Benefits: Smoother, more efficient movement.
Balance and vestibular training.
Description: Static and dynamic balance drills, head turns, and obstacle courses.
Purpose: Reduce falls and improve independence.
Mechanism: Integrates visual, vestibular, and proprioceptive cues.
Benefits: Better community mobility.
Pain-modulating modalities (heat, cold, TENS).
Description: Local heat/cold and transcutaneous electrical nerve stimulation as part of therapy.
Purpose: Reduce aching and allow fuller participation.
Mechanism: Gate-control of pain; decreased muscle spasm.
Benefits: Less medication needed; better tolerance.
Occupational therapy for ADLs and fine motor.
Description: Training for dressing, feeding, handwriting, and play; adaptive tools (built-up grips, button aids).
Purpose: Maximize self-care and school participation.
Mechanism: Repetitive, meaningful tasks drive motor learning.
Benefits: Earlier independence, improved quality of life.
Speech-language and swallow therapy.
Description: Oral-motor exercises, safe-swallow strategies, voice/communication support if brainstem or cranial nerves are involved.
Purpose: Keep nutrition safe and communication clear.
Mechanism: Strengthens bulbar muscles; compensatory postures and textures.
Benefits: Fewer aspiration events; better school and social engagement.

Mind–body approaches

Breathing retraining and paced breathing. Supports calm focus, reduces dyspnea and anxiety, and improves chest wall motion. Mechanism: parasympathetic activation lowers heart rate and muscle tension. Benefits: steadier energy and better participation in therapy.
Mindfulness-based stress reduction (MBSR). Short, daily mindfulness practices to ease worry about weakness. Mechanism: attention training reduces catastrophizing and improves pain coping. Benefits: improved sleep and mood for child and family.
Guided imagery and graded motor imagery. Imagining smooth movement primes real movement. Mechanism: activates motor networks without physical fatigue. Benefits: easier initiation of movement during therapy.
Biofeedback-assisted relaxation. Sensors show heart rate/skin temperature; children learn to reduce arousal. Mechanism: operant conditioning of autonomic responses. Benefits: fewer stress-related pain flares.
Cognitive-behavioral therapy (CBT) for pain and adjustment. Teaches coping skills, pacing, and positive reinforcement. Mechanism: reframes thoughts and behaviors that worsen pain-related disability. Benefits: better adherence and mood.

Educational and caregiver training

Caregiver home-program training. Daily stretching, positioning, brace wear, and skin checks. Purpose: carry gains between sessions. Mechanism: high-frequency practice. Benefits: better long-term outcomes.
Energy-conservation and fatigue management. Spreads tasks across the day; uses mobility aids for distance. Mechanism: keeps effort within safe limits to avoid overuse. Benefits: more participation in school and play.
School IEP/504 planning. Seating, writing supports, elevator access, rest breaks, therapy at school. Mechanism: reduces activity barriers. Benefits: continuous learning with fewer absences.
Safe transfer and mobility training. Caregivers learn proper body mechanics and use of gait belts and wheelchairs. Mechanism: prevents falls and injuries. Benefits: safety and confidence at home.
Community participation planning. Return-to-play rules, adapted sports, and social inclusion strategies. Mechanism: structured exposure. Benefits: resilience and well-being.

Note: AFM care is individualized. Therapies are selected based on neuro exam, MRI, EMG, and respiratory status in line with current guidance. CDCWashington State Department of Health

Drug treatments

Important: No medicine has proven to cure AFM. Some medicines may be tried on a case-by-case basis, mainly to control symptoms or as time-sensitive trials during the acute phase. Doses below are typical references; clinicians adjust for age, weight, kidneys, and interactions.

Intravenous immunoglobulin (IVIG).
Class & purpose: Polyclonal antibodies; attempted immune modulation early in suspected viral-triggered AFM.
Typical dosing/time: Common neurologic dosing is 2 g/kg divided over 2–5 days.
Mechanism: Neutralizes circulating pathogens/toxins; modulates complement and Fc receptors.
Side effects: Headache, fever, thrombosis risk, aseptic meningitis, hemolysis (rare).
Evidence note: Widely used but benefit in AFM remains unproven; discuss risks/benefits. CDC
High-dose corticosteroids (e.g., methylprednisolone).
Class & purpose: Anti-inflammatory glucocorticoid; sometimes used acutely.
Dose/time: 20–30 mg/kg/day (max 1 g/day) for 3–5 days is typical “pulse” for neuroinflammation.
Mechanism: Dampens immune-mediated edema.
Side effects: Hyperglycemia, mood changes, infection risk.
Evidence: Controversial in AFM; many centers limit or avoid routine use. CDC
Antiviral trial agents (e.g., pleconaril/pocapavir—investigational).
Class & purpose: Capsid-binding enterovirus antivirals; studied under research or compassionate protocols.
Dose: Protocol-specific.
Mechanism: Blocks viral uncoating/entry.
Side effects: GI upset, liver enzyme changes; drug interactions.
Evidence: No approved antiviral for AFM; use only in trials/with ID specialists. CDC
Gabapentin.
Class & purpose: Neuropathic pain modulator.
Dose: Start low (e.g., 5–10 mg/kg/day divided), titrate as tolerated.
Mechanism: α2δ calcium-channel subunit modulation -> reduced neuronal excitability.
Side effects: Sedation, dizziness.
Pregabalin. Similar purpose/mechanism; lower pill burden; watch for edema and sedation.
Amitriptyline or nortriptyline (night dosing).
Class: Tricyclic antidepressant for neuropathic pain and sleep.
Dose: Pediatric low starting doses (e.g., 0.1–0.2 mg/kg qHS).
Mechanism: Serotonin/norepinephrine reuptake inhibition; sodium-channel effects.
Side effects: Dry mouth, constipation, QT prolongation risk.
Baclofen.
Class: Antispasticity agent (for later spasticity or painful spasms).
Dose: Small daytime doses titrated slowly.
Mechanism: GABA-B agonism reduces spinal reflex overactivity.
Side effects: Sedation, hypotonia.
Tizanidine.
Class: α2-agonist antispasticity medicine.
Dose: Start 2 mg at night; titrate.
Mechanism: Reduces polysynaptic reflexes.
Side effects: Sleepiness, low blood pressure, LFT elevation.
Botulinum toxin type A (focal).
Class: Neuromuscular blocker for focal contractures later in recovery.
Dose: Units/kg by muscle.
Mechanism: Blocks acetylcholine release at the neuromuscular junction.
Side effects: Local weakness; rare spread effects.
Acetaminophen and NSAIDs.
Purpose: Baseline analgesia and fever control.
Dose: Standard pediatric dosing per weight.
Risks: Liver toxicity with acetaminophen overdose; GI/renal risks with NSAIDs.
Opioids (short term, severe pain).
Purpose: Rescue analgesia in acute care.
Risks: Sedation, constipation, dependence; use sparingly under close monitoring.
Clonidine or guanfacine (sleep/anxiety, dysautonomia).
Mechanism: Central α2-agonism; calms sympathetic surges.
Risks: Hypotension, sedation.
Proton-pump inhibitor or H2 blocker.
Purpose: Stress ulcer prophylaxis in ICU/immobility.
Side effects: Headache; long-term microbiome effects—use when indicated.
Low-molecular-weight heparin (VTE prophylaxis when appropriate).
Purpose: Prevent clots during prolonged immobility in older/larger patients.
Note: Pediatric dosing is protocolized.
Antibiotics/antivirals for intercurrent infections (targeted only).
Purpose: Treat proven bacterial pneumonia, UTI, or influenza/COVID if present; not for AFM itself.
Evidence reminder: AFM has no proven drug cure; management is supportive plus selected trials. CDC

Dietary and “molecular” supplements

Discuss with the care team before starting any supplement, especially in children.

Protein (1.2–1.5 g/kg/day total intake). Supports muscle repair and immune function; mechanism: provides amino acids for myofibril synthesis; benefit: preserves lean body mass during rehab.
Omega-3 fatty acids (fish oil; ~1–2 g/day EPA+DHA in teens/adults; pediatric by weight). Anti-inflammatory eicosanoid profile; may aid nerve membrane health; watch bleeding risk.
Vitamin D (per level; often 600–2000 IU/day maintenance). Immune modulation and bone health during reduced weight-bearing; avoid megadoses without labs.
Vitamin B12 (only if low; typical 250–1000 µg/day oral). Myelin and nerve metabolism; test and treat deficiency.
Folate and B-complex (if dietary gaps). Supports methylation pathways involved in nerve repair; avoid oversupplementation.
Magnesium (e.g., glycinate/citrate 100–200 mg at night in older children/adolescents). Helps cramps and sleep; caution in renal disease.
Creatine monohydrate (adolescents/adults; 3–5 g/day). Improves high-energy phosphate availability in muscle; may support training tolerance.
Coenzyme Q10 (100–200 mg/day in older kids/teens). Mitochondrial cofactor; potential fatigue support; limited evidence.
Alpha-lipoic acid (300–600 mg/day in adults; pediatric use specialist-guided). Antioxidant studied in neuropathies; may help dysesthesia; monitor sugar levels.
Probiotics (strain-specific). Supports gut health during stress, reduced mobility, or after antibiotics; mechanism: microbiome modulation; choose pediatric-appropriate products.

Regeneration-focused therapies

These are research or highly specialized options; availability varies, and none are established cures for AFM.

High-titer anti-enterovirus IVIG or convalescent plasma (experimental). Function: provide neutralizing antibodies against suspected viruses (e.g., EV-D68). Mechanism: passive immunity; may reduce viral spread early. Evidence: case-based; not standard. CDC
Monoclonal antibodies targeting EV-D68 capsid (preclinical/early translational). Function: precise viral neutralization. Mechanism: blocks cell entry. Evidence: laboratory/early translational only.
Type I interferon–based antivirals (trial settings). Function: boost antiviral state in cells. Mechanism: upregulates interferon-stimulated genes. Evidence: investigational.
Mesenchymal stromal/stem cell therapy (experimental). Function: paracrine anti-inflammatory and trophic support. Mechanism: cytokine/EV release; possible neuroprotection. Evidence: small studies in other neurologic disorders; AFM data are sparse.
Neural progenitor cell approaches (research). Function: attempt to restore motor neuron circuits. Mechanism: cell replacement/integration (theoretical). Evidence: preclinical.
Neurotrophin mimetics (e.g., BDNF/NGF pathway agents—research). Function: support axon sprouting and synaptic stability. Mechanism: Trk receptor signaling. Evidence: experimental only.

Procedures and surgeries

Nerve transfer surgery.
Procedure: Surgeons reroute a working donor nerve fascicle to a paralyzed target nerve (e.g., ulnar to musculocutaneous to restore elbow flexion). Timing is typically months after onset once EMG/MRI confirm poor reinnervation.
Why it’s done: To restore critical functions such as elbow flexion or shoulder abduction when spontaneous recovery is unlikely.
Evidence: Recent series show meaningful strength recovery in selected AFM patients compared with natural history. PubMedPedneur
Tendon transfer and soft-tissue balancing.
Procedure: Move a functioning tendon to replace a paralyzed one; release tight tendons to correct deformity.
Why: Improve hand grasp, wrist extension, foot clearance, or correct equinus/hamstring contractures.
Orthopedic contracture release.
Procedure: Surgical lengthening of severely stiff muscles/tendons or joint capsulotomy after failed conservative care.
Why: Reduce pain, allow bracing, and improve seating/standing.
Airway and breathing procedures (tracheostomy; diaphragm pacing in select cases).
Procedure: Secure airway and support ventilation if brainstem/diaphragm weakness persists.
Why: Safety, comfort, and independence from prolonged invasive ventilation.
Feeding tube (gastrostomy) when bulbar weakness prevents safe nutrition.
Procedure: Place a tube to the stomach for nutrition and medicines.
Why: Maintain growth and reduce aspiration risk.

Prevention points

Wash hands often, especially during respiratory virus seasons.
Keep up to date on routine vaccines, including polio and other childhood shots; while polio vaccine does not prevent AFM, it prevents polio, which also causes paralysis.
Stay home when sick and avoid close contact with sick people.
Clean high-touch surfaces and shared items.
Improve indoor air (open windows, use HEPA filtration) during outbreaks.
Consider masks in crowded indoor settings when respiratory viruses are surging.
Teach children to avoid touching the face and to cover coughs/sneezes.
Seek early care for sudden limb weakness after a cold-like illness.
Use safe water and good hygiene during travel.
Follow local health updates on AFM/enterovirus activity. CDC+1

When to see doctors

Seek urgent medical care (ER) now if a child or adult has any of the following, especially within a week of a fever or respiratory illness: sudden arm or leg weakness; facial droop or slurred speech; trouble lifting the head; neck or back pain followed by weakness; difficulty breathing, swallowing, or handling saliva; new problems walking; or sudden bowel/bladder changes. Quick evaluation with a neurologic exam, spinal MRI focused on gray matter, and early lab/CSF testing helps confirm the diagnosis and guide care at a center with AFM experience. PubMed

What to eat and what to avoid

Aim for balanced meals rich in protein to support muscle healing (eggs, dairy, beans, poultry, fish).
Include omega-3 sources (salmon, sardines, walnuts) several times per week.
Choose high-fiber carbs (oats, brown rice, fruit/vegetables) to prevent constipation from immobility or medicines.
Stay well-hydrated; encourage small frequent fluids; use thickened liquids if recommended by speech therapy.
Add calcium and vitamin D sources for bone health during reduced weight-bearing.
If appetite is low, use nutrient-dense snacks and consider dietitian-guided supplements.
Limit ultra-processed foods, excess sugar, and very salty snacks that worsen fatigue or swelling.
Avoid alcohol in teens/adults while on sedating or liver-metabolized medicines.
Avoid “mega-dose” supplements unless a clinician prescribes them.
Follow any swallow-safety texture modifications provided by speech therapy.

Frequently asked questions

1) What causes AFM?
AFM is strongly linked to certain enteroviruses, especially EV-D68 and EV-A71, after a respiratory illness. Not all AFM cases have a virus found, but the pattern and studies support this link. PMC+1

2) Is it the same as polio?
No. It is “polio-like” but not caused by poliovirus. Polio vaccination remains essential for polio prevention. MedlinePlus

3) How common is AFM?
It is rare. Since 2014, the CDC has confirmed hundreds of cases in the U.S., with small numbers each year and occasional spikes. CDC

4) What are the key symptoms?
Sudden limb weakness with low muscle tone and absent reflexes, often after a cold; sometimes facial weakness, trouble speaking or swallowing, and breathing problems. CDC

5) How is AFM diagnosed?
Neurologic exam, MRI of the spinal cord showing gray-matter lesions, lumbar puncture (CSF), and tests for viruses from the nose/throat, stool, blood, and CSF. EMG/nerve studies help later. PubMed

6) Is there a cure?
No approved cure yet. Care is supportive, time-sensitive, and rehabilitation-focused. CDC

7) Do most kids recover?
Recovery varies. Many improve; some have lasting weakness. Early rehab and selected procedures can improve function. CDC

8) Are steroids or IVIG helpful?
They are sometimes used early, but the benefit is uncertain; decisions are individualized with neurology and infectious disease teams. CDC

9) What about plasma exchange (PLEX)?
It is a procedure used for some immune neurologic diseases; routine use in AFM is debated and generally not recommended by CDC; center practices differ. Discuss risks/benefits with specialists. CDC

10) Can surgery help?
Yes, in selected children with limited reinnervation, nerve transfer or tendon procedures can restore key functions like elbow bending or hand opening. PubMedPedneur

11) Is AFM contagious?
AFM is a syndrome; the viruses that precede it spread like common respiratory viruses. Good hygiene reduces risk. CDC

12) Can adults get AFM?
Yes, but children are affected more often. PubMed

13) What is the timeline for rehab?
Rehab starts in the hospital and continues for months to years, depending on recovery and goals.

14) Will my child return to school or sports?
Most children return to school with supports (IEP/504). Adapted sports and gradual return plans are common.

15) What’s being done in research?
Enhanced surveillance, viral studies, and trials of targeted antivirals and surgical/restorative strategies are ongoing. CDCPMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 06, 2025.

PDF Documents For This Disease Condition

References

SaveSavedRemoved 0